Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Notes underwriting agrmnt
Inv. presentation
Asset disposition
Appointed CFO
Quarterly results
Director departure
Appointed director

ARCA biopharma, Inc. (ABIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/21/2023 8-K Quarterly results
07/21/2023 10-Q Quarterly Report for the period ended June 30, 2023
04/24/2023 8-K Quarterly results
04/24/2023 10-Q Quarterly Report for the period ended March 31, 2023
02/24/2023 8-K Quarterly results
Docs: "ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ • Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westminster, CO, February 24, 2023 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2022 financial results and provided a corporate update. In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor to explore and evaluate strategic options for maximizing stockholder value. Potentia..."
02/24/2023 10-K Annual Report for the period ended December 31, 2022
02/13/2023 8-K Quarterly results
02/08/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 CONWAY ROBERT E (Director) has filed a Form 4 on ARCA biopharma, Inc.
Txns: Granted 6,000 options to buy @ $2.32, valued at $13.9k
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
12/19/2022 8-K Quarterly results
12/09/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/09/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/09/2022 8-K Quarterly results
11/03/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/03/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/28/2022 8-K Quarterly results
10/28/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/20/2022 8-K Quarterly results
08/02/2022 8-K Quarterly results
Docs: "Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westminster, CO, August 2, 2022 – ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are in the process of evaluating options for creating stockholder value, including potential development of our assets, partnering and other strategic options.” In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor to explore and evaluate s..."
08/02/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/08/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/08/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
07/08/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
06/21/2022 4 Ma-Weaver Jacob (10% Owner) has filed a Form 4 on ARCA biopharma, Inc.
Txns: Granted 12,000 options to buy @ $2.27, valued at $27.2k
06/21/2022 3 Ma-Weaver Jacob (10% Owner) has filed a Form 3 on ARCA biopharma, Inc.
06/21/2022 SC 13D/A Funicular Fund, LP reports a 17.9% stake in ARCA biopharma, Inc.
06/21/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy